GPP
RCKT icon

Great Point Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Great Point Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-451,000
Closed -$8.83M – 50
2022
Q4 		$8.83M Buy
+451,000
New +$8.31M 1.73% 24

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Great Point Partners's RCKT Position: Q1 2022 in Review

Great Point Partners sold out of Rocket Pharmaceuticals (RCKT) in Q1 2022, closing a stake of 500,526 shares — an estimated $10.9M sold.

Great Point Partners first reported a position in RCKT in Q3 2016 and held it in 7 quarters. The position peaked at $38.4M in Q4 2020. 149 funds tracked by Wall St. Rank hold RCKT as of Q1 2022.

  • Great Point Partners reported no remaining Rocket Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Great Point Partners sold 500,526 Rocket Pharmaceuticals shares in Q1 2022, an estimated $10.9M.
  • Great Point Partners first reported a position in Rocket Pharmaceuticals in Q3 2016 and held it in 7 quarters.
  • Great Point Partners's Rocket Pharmaceuticals position peaked at $38.4M in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2022.

Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.